• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
PCSK9 inhibitors and aging: Does chronological age matter?前蛋白转化酶枯草溶菌素9抑制剂与衰老：实际年龄重要吗？
Atherosclerosis. 2025 Sep;408:120428. doi: 10.1016/j.atherosclerosis.2025.120428. Epub 2025 Jul 9.
2
Social and environmental predictors of gut microbiome age in wild baboons.野生狒狒肠道微生物群年龄的社会和环境预测因素
Elife. 2025 Apr 17;13:RP102166. doi: 10.7554/eLife.102166.
3
Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis.24 小时活动周期是否影响血浆 PCSK9 浓度？系统评价和荟萃分析。
Curr Atheroscler Rep. 2020 Jun 16;22(7):30. doi: 10.1007/s11883-020-00843-x.
4
Reproduction and preference to macronutrients have different relations to biological or chronological age in Drosophila.在果蝇中，繁殖能力以及对大量营养素的偏好与生物年龄或实足年龄有着不同的关系。
Biogerontology. 2025 May 26;26(3):116. doi: 10.1007/s10522-025-10259-2.
5
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
6
Clarifying the biological and statistical assumptions of cross-sectional biological age predictors: an elaborate illustration using synthetic and real data.厘清横向生物学年龄预测指标的生物学和统计学假设：使用合成与真实数据的详细说明。
BMC Med Res Methodol. 2024 Mar 8;24(1):58. doi: 10.1186/s12874-024-02181-x.
7
Assessing thyroid health: phenotypic age compared to chronological age.评估甲状腺健康：表型年龄与实际年龄的比较。
Front Endocrinol (Lausanne). 2025 Jul 4;16:1594139. doi: 10.3389/fendo.2025.1594139. eCollection 2025.
8
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.用于心血管疾病一级和二级预防的前蛋白转化酶枯草溶菌素9单克隆抗体
Cochrane Database Syst Rev. 2017 Apr 28;4(4):CD011748. doi: 10.1002/14651858.CD011748.pub2.
9
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂对高危糖尿病患者血脂水平及心血管事件的影响
Cureus. 2025 Jun 18;17(6):e86310. doi: 10.7759/cureus.86310. eCollection 2025 Jun.
10
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.PCSK9 抑制剂联合或不联合他汀类药物与依折麦布用于心血管风险降低的治疗：一项系统评价和网络荟萃分析。
BMJ. 2022 May 4;377:e069116. doi: 10.1136/bmj-2021-069116.

本文引用的文献

1
Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry.前蛋白转化酶枯草溶菌素9单克隆抗体在老年患者中的疗效和安全性：一项真实世界注册研究
Atherosclerosis. 2025 Sep;408:120229. doi: 10.1016/j.atherosclerosis.2025.120229. Epub 2025 May 26.
2
Editorial for "Managing Hypercholesterolemia in Adults Older Than 75 Years Without a History of Atherosclerotic Cardiovascular Disease. An Expert Clinical Consensus From the National Lipid Association and American Geriatrics Society".《管理75岁以上无动脉粥样硬化性心血管疾病病史成年人的高胆固醇血症。美国国家脂质协会和美国老年医学会的专家临床共识》社论
J Am Geriatr Soc. 2025 Jun;73(6):1663-1664. doi: 10.1111/jgs.19452. Epub 2025 Apr 10.
3
Long-Term Lipid Lowering With Evolocumab in Older Individuals.在老年个体中使用依洛尤单抗进行长期降脂治疗。
J Am Coll Cardiol. 2025 Feb 11;85(5):504-512. doi: 10.1016/j.jacc.2024.11.019.
4
Representation of Older Adults in the ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.美国心脏病学会/美国心脏协会/心血管造影和介入学会冠状动脉血运重建指南中老年人的代表性情况。
JAMA Netw Open. 2024 Jul 1;7(7):e2421547. doi: 10.1001/jamanetworkopen.2024.21547.
5
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.降低老年患者 LDL 胆固醇的疗效和安全性：一项随机对照试验的系统评价和荟萃分析。
Lancet. 2020 Nov 21;396(10263):1637-1643. doi: 10.1016/S0140-6736(20)32332-1. Epub 2020 Nov 10.
6
Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy.自全生命周期纳入政策以来，心血管疾病试验中老年人的代表性。
JAMA Intern Med. 2020 Nov 1;180(11):1531-1533. doi: 10.1001/jamainternmed.2020.2750.
7
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.根据年龄分析阿利西尤单抗对急性冠状动脉综合征后心血管结局的影响：一项ODYSSEY OUTCOMES试验分析。
Eur Heart J. 2020 Jun 21;41(24):2248-2258. doi: 10.1093/eurheartj/ehz809.
8
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
9
Survival Prognosis in Very Old Adults.高龄老年人的生存预后
J Am Geriatr Soc. 2016 Jan;64(1):81-8. doi: 10.1111/jgs.13838.
10
The intersection between aging and cardiovascular disease.衰老与心血管疾病的交集。
Circ Res. 2012 Apr 13;110(8):1097-108. doi: 10.1161/CIRCRESAHA.111.246876.

PCSK9 inhibitors and aging: Does chronological age matter?

作者信息

Mouslmani Mohammad Al, Nouri Armin, Damluji Abdulla A, Nanna Michael G

机构信息

Department of Hospital Medicine, Yale New Haven Hospital, New Haven, CT, USA.

Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

出版信息

Atherosclerosis. 2025 Sep;408:120428. doi: 10.1016/j.atherosclerosis.2025.120428. Epub 2025 Jul 9.

DOI:10.1016/j.atherosclerosis.2025.120428
PMID:40653388
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12309291/
Abstract
摘要